Thin
1 / 2
Linaclotide is a prescription medicine that has been clinically proven to be effective in treating irritable bowel syndrome (IBS-C) and chronic enteroendocrine syndrome (CIC). Its mechanism of action is to increase intestinal fluid secretion, thereby softening stool and promoting regular bowel movements. This mechanism of action not only promotes bowel movements, but also relieves the discomfort caused by constipation, such as bloating, abdominal pain and straining during bowel movements.
Linaclotide is a guanylate cyclase-C agonist that enhances intestinal fluid secretion and accelerates transit, commonly used in research on chronic constipation and irritable bowel syndrome with constipation (IBS-C).
Linaclotide, approved clinically for chronic idiopathic constipation and IBS‑C, typically comes in microgram doses (e.g., 72 mcg, 145 mcg, 290 mcg capsules in clinical settings). Research applications should reflect standard mg‑to‑mcg scaling and follow rigorous protocols. (Note: This product is intended for research and not for direct clinical application.)
Linaclotide is clinically proven to be effective in treating irritable bowel syndrome with constipation (IBS-C) and chronic enteroendocrine syndrome (CIC).
It acts as a guanylate cyclase-C agonist. Its mechanism of action increases intestinal fluid secretion, which softens the stool and accelerates transit to promote regular bowel movements.
By promoting regular bowel movements, it effectively relieves discomforts commonly caused by constipation, including bloating, abdominal pain, and straining.
In clinical settings, Linaclotide is typically administered in microgram doses, commonly available in 72 mcg, 145 mcg, and 290 mcg capsules.
No, the product described is intended exclusively for research applications following rigorous protocols and standard mg-to-mcg scaling, not for direct clinical use.
